These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 30509271

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE.
    Cardiovasc Diabetol; 2019 Mar 29; 18(1):44. PubMed ID: 30922297
    [Abstract] [Full Text] [Related]

  • 3. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 4. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K, EMBLEM Trial Investigators.
    Cardiovasc Diabetol; 2017 Apr 12; 16(1):48. PubMed ID: 28403850
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K, EMBLEM Investigators.
    Cardiovasc Diabetol; 2021 Jul 31; 20(1):160. PubMed ID: 34332584
    [Abstract] [Full Text] [Related]

  • 9. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG.
    Cardiovasc Diabetol; 2018 Jul 30; 17(1):108. PubMed ID: 30060748
    [Abstract] [Full Text] [Related]

  • 10. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
    Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM.
    Cardiovasc Diabetol; 2017 Oct 23; 16(1):138. PubMed ID: 29061124
    [Abstract] [Full Text] [Related]

  • 11. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators.
    Diabetes Obes Metab; 2014 Feb 23; 16(2):147-58. PubMed ID: 23906415
    [Abstract] [Full Text] [Related]

  • 12. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
    Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Bonilha I, Oliveira DC, Breder JC, Cavalcante P, Moreira C, Moura FA, de Lima-Junior JC, do Carmo HRP, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T, ADDENDA-BHS2 trial investigators.
    Cardiovasc Diabetol; 2021 Mar 26; 20(1):74. PubMed ID: 33771149
    [Abstract] [Full Text] [Related]

  • 13. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
    Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC.
    Cardiovasc Diabetol; 2014 Jan 29; 13():28. PubMed ID: 24475922
    [Abstract] [Full Text] [Related]

  • 14. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study.
    Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, Pagliaccia F, Nerla R, Di Franco A, Manto A, Rocca B, Lanza GA, Crea F, Ghirlanda G.
    Diabetes Obes Metab; 2013 May 29; 15(5):427-31. PubMed ID: 23167274
    [Abstract] [Full Text] [Related]

  • 15. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
    Boncelj Svetek M, Eržen B, Kanc K, Šabovič M.
    J Diabetes Complications; 2017 Mar 29; 31(3):544-550. PubMed ID: 28012835
    [Abstract] [Full Text] [Related]

  • 16. Is GFR decline induced by SGLT2 inhibitor of clinical importance?
    Günes-Altan M, Bosch A, Striepe K, Bramlage P, Schiffer M, Schmieder RE, Kannenkeril D.
    Cardiovasc Diabetol; 2024 May 29; 23(1):184. PubMed ID: 38811998
    [Abstract] [Full Text] [Related]

  • 17. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, Oh TK.
    Diabetes Res Clin Pract; 2019 May 29; 151():65-73. PubMed ID: 30954510
    [Abstract] [Full Text] [Related]

  • 18. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M, Thiele K, Hartmann NK, Schuh A, Altiok E, Möllmann J, Keszei AP, Böhm M, Marx N, Lehrke M.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):6. PubMed ID: 33413355
    [Abstract] [Full Text] [Related]

  • 19. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE.
    Diabetes Obes Metab; 2015 Dec 07; 17(12):1180-93. PubMed ID: 26343814
    [Abstract] [Full Text] [Related]

  • 20. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF, Hackney DJ, Aplin AC, Mundinger TO, Larmore MJ, Castillo JJ, Esser N, Zraika S, Hull RL.
    J Endocrinol; 2021 Feb 07; 248(2):95-106. PubMed ID: 33337344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.